IPF Ofev denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Ofev (nintedanib) for IPF on Medical-Necessity Grounds

Cigna's medical-necessity reviews for Ofev in idiopathic pulmonary fibrosis focus on whether the clinical record clearly establishes the IPF diagnosis, documents disease severity, confirms the prescriber's specialty and involvement, and shows that the treatment plan aligns with current professional guideline recommendations. Denials typically occur when the submitted documentation is incomplete — missing pulmonary function data, lacking a specialist's confirmation of diagnosis, or omitting a chart-supported explanation of why this agent was selected. The denial is almost always a documentation gap, not a clinical judgment that the patient should not receive the drug.

## Why This Denial Is Appealable

Medical-necessity denials are highly fact-sensitive and routinely overturned when the appeal provides what the initial submission lacked. Because IPF is a progressive, irreversible disease with a limited therapeutic window, there is a strong clinical and ethical imperative to supply complete documentation promptly and to invoke expedited review if the patient's condition warrants it.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits. Cigna must decide within 30 days for prospective requests; 60 days for retrospective; 72 hours for expedited.
• External review (ACA §2719): After an adverse internal decision, an independent review organization applies clinical standards independent of Cigna. For most plans the request window is up to four months from the denial notice.
• ERISA §503: Employer-sponsored plans are subject to federal full-and-fair review requirements, including your right to see all evidence Cigna relied on and to submit a rebuttal.
• Expedited review: If your pulmonologist documents that the standard timeline would seriously jeopardize your health, invoke expedited at every level simultaneously.

## Documentation to Gather

1. Diagnosis confirmation — Specialist (pulmonologist) records documenting IPF per the criteria of the applicable professional guideline organization (e.g., ATS/ERS/JRS/ALAT), including HRCT report and pulmonary function testing results. 2. Disease severity — Serial PFT measurements showing progression, six-minute walk test data, or other functional status documentation from the chart. 3. Prior-treatment history — Dates, agents, and outcomes of any prior IPF therapies trialed, or a clinical explanation of why this agent is appropriate as initial therapy. 4. Prescriber medical-necessity letter — Specialist letter confirming diagnosis, disease course, rationale for selecting Ofev, and alignment with current IPF management guidelines; reference the relevant guideline organization generically. 5. Comorbidity context — Any concurrent conditions that influence the treatment choice, as documented in the chart.

## Criteria-Mapping Structure

Download Cigna's current coverage policy for antifibrotic agents in IPF and list every stated criterion. For each one, cite the specific chart note, test result, or letter that satisfies it. Typical criteria to address:

• Confirmed IPF diagnosis by a qualified specialist
• Disease severity consistent with guideline-supported treatment initiation (reference the prescribing label and the applicable guideline organization for the exact thresholds your prescriber used)
• Appropriate prescriber specialty
• Clinical rationale for agent selection
• Monitoring plan

A completed criteria map submitted alongside the specialist letter dramatically reduces the chance that Cigna's reviewer will uphold the denial.